Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ: STIM) reported strong Q2 2025 financial results with total revenue of $38.1 million, representing an 18% adjusted pro forma growth year-over-year. The company achieved record Greenbrook clinic revenue of $23.0 million and reduced cash burn to $3.5 million.
Key highlights include shipping 41 NeuroStar systems at the highest ASP in 5 years (over $85,000), treating over 209,000 global patients, and securing an additional $10 million in funding from Perceptive Advisors. The company reported a net loss of $(0.15) per share and appointed Steven Pfanstiel as new CFO.
For full-year 2025, Neuronetics maintains revenue guidance of $149-155 million, expects gross margin of 48-50%, and projects positive cash flow from operations in Q4 2025.
Neuronetics (NASDAQ: STIM), a medical technology and healthcare company focused on neurohealth therapies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Keith Sullivan, President and CEO, will deliver a presentation on Tuesday, August 12, 2025, at 1:30 PM ET.
The presentation will be accessible to registered attendees and presenting companies through the conference portal for 14 days following the event.
Neuronetics (NASDAQ: STIM) announced significant findings published in JAACAP Open regarding the effectiveness of NeuroStar TMS therapy in treating adolescent and young adult depression. The study, based on the world's largest TMS outcomes dataset, analyzed 1,283 patients aged 12-21 and found that approximately 70% of patients showed clinically meaningful improvement.
Since receiving FDA clearance in March 2024 for treating adolescents aged 15-21, NeuroStar has seen a one-third increase in adolescent treatments. The research demonstrated similar efficacy to adult populations, with less than 1% reporting worsening symptoms. The study is particularly significant as only two FDA-approved medications exist for adolescent depression, both carrying major safety warnings.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, before market open.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss the results. Investors can access the live webcast through the provided link, and telephone participants are encouraged to register and join 10 minutes before the event starts.
Neuronetics (NASDAQ: STIM) has appointed Steven Pfanstiel as its new Chief Financial Officer, effective July 15, 2025. Pfanstiel, who brings over 20 years of healthcare experience, replaces Steve Furlong, who will remain as Senior Advisor to the CEO until his retirement on March 31, 2026.
Pfanstiel most recently served as CFO and COO at Marinus Pharmaceuticals and has held senior financial roles at Lifescan, Optinose, and Johnson & Johnson. As part of his appointment, he received an inducement grant of 400,000 restricted stock units with specified vesting schedules.
The company has reaffirmed its guidance for Q2 and full year 2025, expecting to achieve positive cash flow in Q3 2025. The outlook is supported by successful Greenbrook operations integration and progress in key growth initiatives.
- U.S. clinic revenue: $18.7M (Greenbrook) - Treatment session revenue: $9.6M - NeuroStar System revenue: $2.8M
The company completed an $18.9M secondary offering in February 2025. Notable developments include CFO Steve Furlong's planned retirement in March 2026, major insurance coverage expansions for adolescent TMS treatment, and achieving over 202,000 global patients treated. Despite a Q1 net loss of $(12.7M), Neuronetics projects becoming cash flow positive in Q3 2025.
For 2025, Neuronetics updated guidance to $149.0M-$155.0M in total revenue, with Q2 2025 expected revenue between $36.0M-$38.0M. The company anticipates year-end cash above $20.0M.